ArticleCurrent research in toxicology2025
Prenatal linuron exposure disrupts adrenal steroidogenesis and induces adrenal insufficiency in male rat offspring.
Article in Current research in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linuron, a commonly used agricultural herbicide in certain regions, has raised concerns due to its endocrine toxicity in humans and wildlife. While its gonadal toxicity is established, its direct impact on prenatal adrenal development remains unexplored. Pregnant Sprague-Dawley rats received linuron doses (0, 25, 50, 100 mg/kg/day) by oral gavage from gestational days 12-21. Linuron reduced serum CORT at 50 and 100 mg/kg and ALDO at 100 mg/kg but did not affect ACTH levels. At 100 mg/kg, linuron decreased cell density in the adrenal zona fasciculata without changing its thickness. It also altered the expression of key genes and proteins involved in adrenal function at 50 and/or 100 mg/kg. Additionally, linuron reduced the expression of key antioxidant enzymes (SOD2, GPX1, CAT) at 100 mg/kg. Linuron altered adrenal kinase signaling, activating AMPK but suppressing AKT, with no effect on ERK1/2 pathways. These findings reveal, for the first time, that linuron disrupts male fetal adrenal development and function likely through impaired steroidogenesis, oxidative stress, and dysregulated AKT/AMPK signaling, highlighting its role as a developmental adrenal disruptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.